Making Bank in Biotech — It's So Good

You can make a fortune on biotech stocks if you know what you’re doing. The secret is to be on the right side of the trade. You can make a fortune on biotech stocks if you know what you’re doing. The secret is to be on the right side of the trade. [Energy and Capital logo] Making Bank in Biotech — It's So Good [Christian DeHaemer Photo] By [Christian DeHaemer]( Written May 18, 2021 ImClone Systems was a market darling back in the day. The stock price went from single digits to $170 a share in about a year. [ImClone Chart] ImClone was a biotech company that developed a drug called Erbitux. Today, Erbitux is a cancer medicine that interferes with the spread of cancer cells in the body. The drug is used in combination with other drugs to treat colon and rectal cancer as well as head and neck cancer. It is useful but not a cure-all, and it has competition in the marketplace. Twenty years ago, it was an experimental monoclonal antibody with all the promise of a blockbuster drug that could cure cancer. As you can see from the chart above, the drug showed great promise in Phase 1 and 2 studies. The stock went up 1,600% in a year — a huge winner. FDA Says No However, after Phase 3 trials, the drug failed to get Food and Drug Administration (FDA) approval and the share price cratered. But that wasn’t the problem. People lose money in stocks all the time. The issue was that the nonapproval decision leaked and people sold based on this insider information. It is illegal to trade on an FDA announcement before it is released. The founder of the company, as well as several members of his family, company executives, and Martha Stewart, went to jail for insider trading. The Best Trade Opportunity in a Decade No, it isn’t GameStop, AMC, or any of those other meme stocks. According to Keith Kohl, this $1.1 trillion sector is the best place for traders looking to make money. [Click here to see the details.]( Stewart Can Hang [Martha Looking Hot] For those too young to know, Martha Stewart was a big shot. Before she teamed up with Snoop Dogg, Stewart was a model and then a TV show hostess for cooking and home decorating. Later she became a media mogul and was the founder of Martha Stewart Living Omnimedia (NYSE: MSO). The Martha Stewart company was big in the early 2000s with booming revenue and lots of exposure. So it was a big deal when the SEC came calling. From Wikipedia: Martha Stewart, the founder of Martha Stewart Living Omnimedia, also became embroiled in the scandal after it emerged that her broker, Peter Bacanovic, tipped her off that ImClone was about to drop. In response, Stewart sold about $230,000 in ImClone shares on December 27, 2001, a day before the announcement of the FDA decision. Stewart's involvement would have never come to light had Doug Faneuil, Bacanovic's assistant, not disclosed it to investigators. Although Stewart maintained her innocence, she was found guilty and sentenced on July 16, 2004, to five months in prison, five months of home confinement, and two years' probation for lying about a stock sale, conspiracy, and obstruction of justice. Get Ready for Huge Fed Move (As Soon as June 16) Federal Reserve Chairman Jerome Powell just broke HUGE news... After months of silence, he finally admitted that the Fed is working on a digital dollar. This bombshell move could spell disaster for Bitcoin. But if you know how to position yourself, you could multiply your money by as much as 60 times in the months ahead. I expect truly historic windfalls with a “digital dollar” going live — some investors have already pocketed gains of as much as 1,585%, and that’s just the start. It’s vital you act BEFORE the Fed makes its next big announcement. [Click here for everything you need to know.]( Many people think Stewart got a raw deal, and she did. And the great irony is that Erbitux was later approved by the FDA in 2004, sending ImClone stock back up another 2,000%. The upshot of all this is not that crime doesn't pay but rather that you can make a fortune on biotech stocks if you know what you're doing. FDA approval can make or break even the rich and famous. The secret is to be on the right side of the trade, and to do that you need a system. [Join us for a special summit]( where my good friend Keith Kohl gives you the details on how to trade biotechs the right way. Best regards, [Christian DeHaemer Signature] Christian DeHaemer P.S. Eli Lilly and Company eventually purchased ImClone Systems for $6.8 billion in April 2009. Browse Our Archives [Up to 144 New Stock Opportunities Make This Sector Ripe for Profits]( [What They're Not Telling You About the Colonial Pipeline Cyberattack]( [How to Trade the FDA Approval Game]( [Investing in the End of Pandemics]( [Bold Prediction: Bitcoin to $125,000]( --------------------------------------------------------------- This email was sent to {EMAIL}. It is not our intention to send email to anyone who doesn't want it. If you're not sure why you've received this e-letter, or no longer wish to receive it, you may [unsubscribe here](, and view our privacy policy and information on how to manage your subscription. To ensure that you receive future issues of Energy and Capital, please add newsletter@energyandcapital.com to your address book or whitelist within your spam settings. For customer service questions or issues, please contact us for assistance. [Energy and Capital](, Copyright © 2021, [Angel Publishing LLC](. All rights reserved. 3 E Read Street, Baltimore, MD 21202. The content of this site may not be redistributed without the express written consent of Angel Publishing. Individual editorials, articles and essays appearing on this site may be republished, but only with full attribution of both the author and Energy and Capital as well as a link to www.energyandcapital.com. Your privacy is important to us -- we will never rent or sell your e-mail or personal information. Please read our [Privacy Policy](. No statement or expression of opinion, or any other matter herein, directly or indirectly, is an offer or the solicitation of an offer to buy or sell the securities or financial instruments mentioned. While we believe the sources of information to be reliable, we in no way represent or guarantee the accuracy of the statements made herein. [Energy and Capital]( does not provide individual investment counseling, act as an investment advisor, or individually advocate the purchase or sale of any security or investment. The publisher, editors and consultants of Angel Publishing may actively trade in the investments discussed in this publication. They may have substantial positions in the securities recommended and may increase or decrease such positions without notice. Neither the publisher nor the editors are registered investment advisors. Subscribers should not view this publication as offering personalized legal or investment counseling. Investments recommended in this publication should be made only after consulting with your investment advisor and only after reviewing the prospectus or financial statements of the company in question.